The Patented Medicine Prices Review Board (PMPRB) recently released its March 2018 newsletter (the first since July 2017). Highlights include:
- an update on the PMPRB guidelines to reflect the "future framework envisioned by the PMPRB [which] aspires towards bright line tests that yield ceiling prices that are reasonable and foreseeable to patentees" (for further details please see "Canada releases proposed amendments to patented medicines pricing regulations" and "PMPRB releases scoping paper concerning proposed amended regulations");
- the release of:
- the PMPRB's 2016 annual report (published October 2017);
- Alignment among Public Formularies in Canada – Part 1: General Overview (published October 2017); and
- Generics 360: Generic Drugs in Canada, 2016 (published February 2018); and
- notice that the following publications are to be released in 2018:
- Meds Entry Watch, second edition;
- CompassRx, fourth edition; and
- Potential Savings from Biosimilars in Canada.
For further information on this topic please contact Andrew Mandlsohn at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
